

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 24, 2004

SIGA Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

0-23047

13-3864870

(State or other Jurisdiction of
Incorporation or Organization)

(Commission File
Number)

(I.R.S. Employer
Identification Number)

420 Lexington Avenue, Suite 601, New York, New York

10170

(Address of Principal Executive Offices)

(Zip Code)

(212) 672-9100

(Registrant's telephone number, including area code)

ITEM 7.01. Other Events and Required FD Disclosure.

On August 24, 2004, SIGA issued a press release pursuant to which SIGA announced the receipt of two grants totaling approximately \$12 million from the National Institutes of Health, which will be received over the next two years and will support the development of the biowarfare defense assets recently acquired from VPHM. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated in this Item 7.01 by reference.

ITEM 9. Financial Statements and Exhibits

(c) Exhibits

Exhibit No.	Description
99.1	Press Release dated August 24, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SIGA TECHNOLOGIES, INC.

By: /s/ Thomas N. Konatich

Thomas N. Konatich
Acting Chief Executive Officer and
Chief Financial Officer

Date: August 25, 2004

EXHIBIT INDEX

Exhibit Number -----	Description -----
99.1	Press Release dated June 9, 2004.

Contact:
Thomas N. Konatich
Chief Financial Officer
SIGA Technologies, Inc.
(212) 672-9100

Investor Contact:
Dianne Will
Willstar Consultants, Inc.
(518) 398-6222
dwill@willstar.net

SIGA announces Receipt of \$12 Million in nih funding FOR BIODEFENSE

New York, August 25, 2004 -- SIGA Technologies, Inc. (NASDAQ: SIGA) today announced the receipt of two grants totaling approximately \$12 million from the National Institutes of Health (NIH). The \$12 million in grant funding will be received over the next two years and will support the development of the biowarfare defense assets recently acquired from ViroPharma. The grant awards include funding for the preclinical development of antivirals targeting smallpox and arenaviruses, as well as drug discovery efforts against other hemorrhagic fever viruses such as Ebola. "We are pleased to receive these awards validating SIGA's capabilities to take these research programs to the next level. This support will make a significant impact accelerating development of these important biodefense products," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. Smallpox and arenaviruses are Category A bioterrorism agents, both are considered significant threats due to their ease of transmission, high mortality rates and lack of vaccination. Present treatments for smallpox cannot be administered to the general population without significant risk of adverse reactions. Likewise, no treatment for arenaviruses, (a causative agent of viral hemorrhagic fevers), currently exists.

Bernard L. Kasten, M.D. SIGA's Chief Executive Officer commented that "The award of the \$12 Million in NIH grant funding and the acquisition of ViroPharma's biowarfare defense assets complement SIGA's industry leading position as a developer bioterrorism counter measures for category A Agents."

About SIGA Technologies, Inc.

SIGA Technologies is applying bacterial genomics in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA has the potential of becoming a significant force in the discovery of vaccine and pharmaceutical agents to fight emerging pathogens. SIGA's product development programs emphasize the increasingly serious problem of drug resistant bacteria and emerging pathogens. SIGA's vaccine and drug platforms are based on its pioneering research into the structure, function and processing of bacterial surface proteins. SIGA is leveraging these platforms through multiple strategic partners, the National Institutes of Health and TransTech Pharma. For more information about SIGA, please visit SIGA's Web site at www.siga.com.

This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding the efficacy and intended utilization of SIGA's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to SIGA or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials. More detailed information about SIGA and the factors discussed above is set forth in SIGA's filings with the Securities and Exchange Commission, including SIGA's Annual Report on Form 10-K for the fiscal year ended December 31, 2002, and in other documents that SIGA has filed with the U.S. Securities and Exchange Commission. Investors and security holders are urged to read those documents free of charge at the Commission's web site at www.sec.com. Those documents may also be obtained free of charge from SIGA. SIGA does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.